Compugen (CGEN) Total Non-Current Liabilities (2009 - 2026)
Compugen's (CGEN) quarterly Total Non-Current Liabilities came in at $28.5 million in Q1 2026, down 23.76% year-on-year from $37.3 million in Q1 2025, and down 8.95% quarter-over-quarter from $31.3 million in Q4 2025.
Compugen (CGEN) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Compugen has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $28.5 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $28.5 million, down 23.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.5 million (down 23.76% YoY), and the FY2025 annual result was $31.3 million, down 21.67% from the prior year.
- Total Non-Current Liabilities came in at $28.5 million for Q1 2026 at Compugen, down from $31.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $39.9 million in Q4 2024 to a low of $4.0 million in Q3 2023.
- The 5-year median for Total Non-Current Liabilities is $28.5 million (2026), against an average of $21.3 million.
- Across the five-year window, Total Non-Current Liabilities tumbled 45.34% in 2022 and surged 779.92% in 2024, its largest moves.
- Compugen's Total Non-Current Liabilities stood at $4.6 million in 2022, then jumped by 544.72% to $29.5 million in 2023, then soared by 35.28% to $39.9 million in 2024, then decreased by 21.67% to $31.3 million in 2025, then retreated by 8.95% to $28.5 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $28.5 million (Q1 2026), $31.3 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | 28.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.47 Mn |
| Dec 31, 2025 | 31.27 Mn |
| Sep 30, 2025 | 33.74 Mn |
| Jun 30, 2025 | 35.69 Mn |
| Mar 31, 2025 | 37.34 Mn |
| Dec 31, 2024 | 39.92 Mn |
| Sep 30, 2024 | 35.27 Mn |
| Jun 30, 2024 | 27.06 Mn |
| Mar 31, 2024 | 29.40 Mn |
| Dec 31, 2023 | 29.51 Mn |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | 4.25 Mn |
| Mar 31, 2023 | 4.39 Mn |
| Dec 31, 2022 | 4.58 Mn |
| Sep 30, 2022 | 4.78 Mn |
| Jun 30, 2022 | 5.94 Mn |
| Mar 31, 2022 | 7.08 Mn |
| Dec 31, 2021 | 8.37 Mn |
| Sep 30, 2021 | 7.22 Mn |
| Jun 30, 2021 | 7.55 Mn |